Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SERA PROGNOSTICS, INC. (SERA)

Sera Prognostics Q3 revenue rises to $42,000 as net loss widens to $8.1 million

Mixed Impact 3 of 5 earnings Written later

Sera Prognostics reported third-quarter 2026 results for the period ended September 30, 2026. Test revenue rose 163% year over year to $42,000, but the net loss widened to $8.1 million, and the company said revenue was held back by lower average selling prices from a higher mix of low or non-reimbursed tests.

Key points

  • Cash, cash equivalents and marketable securities were $72.8 million at quarter end, with Q3 operating cash burn of $7.3 million.
  • Florida Medicaid added the PreTRM test to its covered list and fee schedule, bringing covered Medicaid lives to about 7 million, following Illinois, which set a $525 fee schedule rate.

The filing

CompanySERA PROGNOSTICS, INC. (SERA)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:10 PM ET
Accession number0001534969-26-000038

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.